Article
Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.
Psychiatry research - 1 Aug 2017
Jung Jeesun, Tawa Elisabeth A, Muench Christine, Rosen Allison D, Rickels Karl, Lohoff Falk W
Abstract excerpt
We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
